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Targeted Nanoblobs Spot Treat
Cancer and Heart DiseaseNanoprobes that can be injected into
your body to diagnose and treat dis-
ease have a distinguished history in
science fiction. Raquel Welch glam-
orized nanomedicine in the 1966
movie Fantastic Voyage, based on
the IsaacAsimovbook about aminia-
turized submarine’s journey through
a human body. An underrated pre-
cursor was George S. Chapell’s
1930 travelogueThrough theAlimen-
tary Canal with Gun and Camera.
Until recently, nanomedicine was
more fiction than science. But in Jan-
uary 2005, Abraxane, a suspension
of albumin bound paclitaxel nano-
particles for the treatment of meta-
static breast cancer, was approved
by the FDA. Abraxane and its ilk are
the vanguard of a new generation
of advanced therapies that use
multifunctional nanoparticles to si-
multaneously diagnose early-stage
disease while administering and
monitoring targeted treatment.
St. Louis-based Kereos (http://
www.kereos.com/) engineers the
surface of nanoparticles to carry
contrast agents for magnetic reso-
nance imaging (MRI), in addition to
drug molecules aimed at destroying
minute cancer tumors as well as ar-
terial plaque. The company’s tech-
nology platform is licensed from
intellectual property developed at
Washington University School of
Medicine by company cofounders
Dr. Samuel Wickline, professor, and
Dr. Gregory Lanza, associate profes-
sor at the university. Kereos has also
been developing tailored MRI con-
trast agents in collaboration with
Philips Medical Systems, a major
player in medical diagnostics.
Currently, Kereos has four prod-
ucts in the pipeline. KI-0001 is an
MRI contrast enhancement agent
for tumor detection, and KI-1001 is
a highly selective chemotherapeutic
agent. Last year, Bristol-Myers
Squibb Medical Imaging licensed
KI-0002, Kereos’ cardiovascular pla-
que MRI imaging agent. ‘‘They are
developing a very similar productthat is targeted to a different bio-
marker, one that is involved in car-
diovascular disease,’’ says Kereos
President and CEO, Robert Beards-
ley. Kereos is also developing KI-
1003, a therapeutic agent for arterial
plaque.
‘‘Abraxane and its ilk are
the vanguard of a new
generation of advanced
therapies that use multi-
functional nanoparticles
to simultaneously diag-
nose early-stage disease
while administering and
monitoring targeted treat-
ment.’’
Beardsley projects the potential
market for KI-0001 as between $100
to $250 million. He estimates a billion
dollar market for the chemothera-
peutic KI-1001. These are attractive
numbers for investors—Kereos
raised over $20 million in Series B
venture funding in the fall of 2005.
The company is backed by a consor-
tium of investors including Genen-
tech and Royal Philips Electronics,
Harris & Harris, Prolog Ventures,
Triathlon Medical Ventures, Charter
Life Sciences, and Rivervest Venture
Partners.
Hitting the Magnetic Moment
New contrast agents are sought
after because they expand the capa-
bilities of magnetic resonance imag-
ing. MRI or nuclear magnetic reso-
nance (NMR) imaging is a sensitive
way of detecting abnormal or can-
cerous cells as well as the inflamma-
tion associated with the growth of
unstable arterial plaque. Traditional
MRI probes the magnetic relaxation
of the water hydrogen nucleus’s
‘‘magnetic moment’’ under the influ-ence of an external magnetic field.
This ‘‘magnetic moment’’ is gener-
ated by the spin of a subatomic
particle or cluster of subatomic par-
ticles such as a nucleus. MRI mea-
sures the time it takes the hydrogen
nucleus to relax back to equilibrium
after a magnetic pulse is applied,
a parameter called T2. This relaxa-
tion time is exquisitely sensitive to
the chemical environment inside
the cell or tissue. Most types of
cancer give different signals than
healthy cells; the drawback is that
their spatial resolution is not great,
and cost of MRI equipment and op-
eration is prohibitive. Additionally,
it is almost impossible to follow met-
abolic or organ processes in the
body with MRI. A paramagnetic con-
trast agent may partially solve this
problem because it generates a bet-
ter signal-to-noise ratio [1]. Thus, us-
ing a paramagnetic contrast agent
such as gadolinium, which can sub-
stantially influence the local relaxa-
tion time of the hydrogen nuclei, is
valuable in imaging elusive tumors
and incipient arterial plaque [2]. All
the imaging companies are inter-
ested in contrast agents because
they want to enhance the capabil-
ities of their standard equipment
and create lower-end versions to
expand their markets.
Nanoblobs to the Rescue
Kereos produces its contrast agents
in an emulsion. The emulsion is gen-
erated by homogenizing an aqueous
suspension of surfactant and oil.
Most of the surfactant is a standard
perfluorocarbon amphiphile that
serves as a homogenizer. But a small
portion of the surfactant is a proprie-
tary amphiphilic molecule that has
functional moieties such as chelated
gadolinium ions or paclitaxel mole-
cules attached to its hydrophilic
part. The homogenization process
produces globules of about 250 nm
in diameter, coated by a monolayer
of amphiphilic molecules with their
hydrophilic parts pointing outward.
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surface is studded by the functional
ligands. Because the process is
simple, several types of functional
amphiphiles can be added simulta-
neously to the suspension in the
process of homogenization.
For targeting cancer cells, the li-
gands incorporated into the emul-
sion have high binding affinity for a
class of cell-surface proteins called
integrins, in this case, the bio-
markers avb3, which are expressed
only on the surface of blood vessels
that feed tumors and arterial plaque
by angiogenesis. ‘‘Our approach is
to just use the integrin as a zip
code, if you will, an address to which
we send a potent chemotherapeutic
or potent imaging agent,’’ says Tim-
othy J. Pelura, Kereos CTO. ‘‘And
the reason why ours is a big im-
provement is because of the amplifi-
cation effect. They [the nanopar-
ticles] have a tremendous surface
area, which enables them to carry a
tremendous amount of either these
imaging or chemotherapeutic mole-
cules, per emulsion droplet.’’ Ac-
cording to Pelura, this approach
enables Kereos to image tumors of
1 to 2 mm in diameter.
To better understand how con-
trast is generated, imagine how
a traffic jam appears to a pilot who
flies over a highway at night. The
area where the traffic is most con-
gested will appear the brightest.
The emulsion droplet with its load
of functional groups lingers longer
at the target site, resulting in a higher
local concentration of active mate-
rial, producing higher imaging con-
trast or a higher local concentration
of chemotherapeutic agent. Accord-
ing to Pelura, each of the particles
has about 100 targeting ligands on
its surface, increasing the chances
that they interact with the avb3 integ-
rins on the surface of the blood ves-
sels as they flow through them. He
said this method can deliver an effi-
cient dose of paclitaxel to the tumor
at 1/100th the dose of conventional
chemotherapy, resulting in fewer
side effects for the patient.
Because the chelated gadolinium
imaging agent is water soluble, it
can be expelled by the kidneys in
about 24 to 36 hr. The FDA takes
a dim view of particles that loiter in
the body, so for this type of therapy
to work, the nanoparticles must ei-
ther be expelled or metabolized.‘‘Molecules are self-assembling and
self-disassembling, so we don’t
have all the problems in regards to
distributions and ejection from the
body that the real nanotech people
do,’’ says Pelura.
So far, Kereos has tested its emul-
sions in rabbit, mouse, and rat
models. The cancer contrast agent
KI-0001 will undergo IND testing
and human trials at the end of this
year. The chemotherapeutic KI-1001
will undergo a small trial of 15 to 20
patients this year as well. The car-
diac plaque agent KI-1003 is in lon-
ger term development. ‘‘Where we
think it may be used in humans is
in patients who are predisposed to
heart attack or stroke,’’ says Pelura.
Corralling Particles
TheNationalCancer Institute’sNano-
technology Alliance Initiative funds
researchers through eight interdisci-
plinary centers and 12 platform
grants. One center is headed by Dr.
Wickline with Dr. Lanza as a principal
investigator. The researchers had
developed Kereos’ perfluorocarbon
emulsions with funding through
NCI’s Unconventional Innovations
Program. ‘‘Larger pharmaceutical
companies are watching this pro-
cess,’’ says Dr. Piotr Grodzinski, Di-
rector of Nanotechnology for Cancer
programs at NCI. ‘‘They want to see
how it matures. In reality, a lot of the
basic commercialization is going on
through startups.’’
Drug Molecules Hitch Rides
on the Magic Bus
Dr. Francis C. Szoka, Professor of
Biopharmaceutical Sciences and
Pharmaceutical Chemistry at the
University of California San Fran-
cisco, has explored various methods
for macromolecular drug delivery in
his career, as evinced by the picture
of the psychedelic bus on his depart-
ment website. A method for encap-
sulating doxorubicin in a ‘‘stealth li-
posome,’’ developed by Sequus,
the company he founded, was ap-
proved by the FDA for Karposi’s sar-
coma in 1996 and ovarian cancer in
2005. According to Szoka, tumors
are simply very permeable to mole-
cules in the blood because the
endothelial cells that line the blood
vessels that feed them are poorly
formed, so there is leakage from
blood to tumor. Molecules can enter
and are retained because tumorsdon’t have a well-developed lym-
phatic system.
Szoka has now turned to den-
drimers for their promising attri-
butes. A dendrimer is a cunning little
polymer molecule that like a tum-
bleweed, has a multigenerational
branched fractal structure and can
be decorated with drug molecules
and contrast agents to become
a tiny nanoweapon to fight disease.
Although a liposome, which is es-
sentially a tiny sac of fat, can span
100 nm, dinky dendrimers are about
5–10 nm in diameter. ‘‘In theory, be-
cause of their smaller size, they can
get into places that liposomes can’t
reach,’’ Szoka says. He explained
that as drug molecules can be at-
tached covalently, different drugs
with different properties can be re-
leased at the same controlled rate
from the same dendrimer. Either
the dendrimer metabolizes at the
target, releasing the drug, the bond
that attaches the drugs to the den-
drimer is broken at the target site,
or the attached drugs function on
the dendrimer itself, rather like
a double-edged sword.
According to Szoka, one cannot
assume that particles, even the
size of a protein, like dendrimers,
will be free of biological effects [3].
‘‘It is not nice to fool Mother Nature,’’
he says. When using nanoparticles,
Szoka explains, one always has to
balance permeability and residence
time. If the particle is smaller than
the pores in the kidney, it will have
a shorter residence time in the
blood, and hence the effectiveness
drops. Szoka and his coinvestigator,
Professor Jean Frechet of the Uni-
versity of California Berkeley chem-
istry department are interested in
dendrimers that have more than
six or seven generations and are
made of biodegradable polyester.
He says a key unanswered ques-
tion about biodegradable den-
drimers is how many chemical steps
are necessary to make them. ‘‘I
would say there is not enough infor-
mation published yet to discriminate
among the different approaches,’’
Szoka says.
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